| Business Summary | | Esperion
Therapeutics,
Inc.
is
a
biopharmaceutical
company
dedicated
to
the
discovery
and
development
of
products
for
the
treatment
of
cardiovascular
and
metabolic
diseases.
The
Company
has
focused
its
initial
drug
development
and
discovery
activities
on
a
novel
class
of
drugs
to
treat
acute
and
chronic
cardiovascular
diseases.
The
Company
intends
to
commercialize
a
novel
class
of
drugs
that
focus
on
a
new
treatment
approach
the
Company
calls
HDL
Therapy,
based
upon
its
understanding
of
high
density
lipoprotein
(HDL)
function.
Currently,
the
Company
is
working
on
five
product
candidates:
LUV,
AIM,
RLT
Peptide,
ProApo
A-1
and
HDL
Elevators,
each
designed
to
enhance
the
naturally
occurring
processes
in
the
body
that
remove
excess
cholesterol
from
arterial
walls.
The
Company
initiated
clinical
trials
with
two
of
its
product
candidates
in
2000
and
expects
to
initiate
clinical
testing
on
additional
product
candidates
in
2001. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Esperion
Therapeutics,
Inc.
is
a
development
stage
pharmaceutical
company
engaging
in
research
and
development
of
pharmaceutical
product
candidates
for
cardiovascular
disease.
For
the
six
months
ended
6/30/01,
revenues
were
unchanged
at
$0.
Net
loss
applicable
to
Common
fell
64%
to
$12.3
million.
Results
reflect
the
lack
of
any
revenue
generating
drugs,
the
absence
of
$22.9
million
in
beneficial
preferred
stock
conversion
costs
and
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| David Scheer, 48 Chairman | -- | -- | Roger Newton, Ph.D., 50 Pres,
CEO, Director | $280K | -- | Timothy Mayleben, 40 VP-Fin.,
CFO | 211K | $238K | Charles Bisgaier, 47 VP,
pharmacology | 160K | 393K | Jean-Louis Dasseux, P.h.D., 42 VP,
worldwide chemistry and technologies | 179K | 79K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|